R evolution Medicines  Expect s  to  Conduct  Late-Stage   Development of  RAS(ON)  I nhibitor  Drug  C andidate  Pipeline   Supported by  Fortified Balance Sheet Agreement is the Result of a  Rigorous  Process Conducted by Independent Transaction Committee of EQ Rx  Board to Consider Strategic

Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapies Prioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today

For Investors Lerociclib: Ongoing Phase 2 trial in first- and second-line treatment of metastatic breast cancer; expect to initiate Phase 3 trial in advanced endometrial cancer in 1H 2023 Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC Sugemalimab: MAAs accepted for

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced